Nanomerics announced the end of dosing with all volunteers completing 28 consecutive days of administration in its OC134 Phase I trial – the SUNLIGHT trial.
The volunteers were dosed every 12 hours with MET eye drops and OC134 eye drops commenced in December 2024 and was completed in January 2025. No adverse events of moderate or severe severity reported during the clinical phase of the trial and there were no clinically significant individual changes.
Dr Nand Singh, Medical Director at Quotient Sciences commented, “We are pleased that the First-In-Human trial has completed the clinical phase of the study at our Nottingham, UK clinic for Nanomerics’ OC134 Phase 1 SUNLIGHT trial. This trial marks a significant milestone in the development of a new therapeutic approach aimed at developing advanced treatments for moderate to severe allergic conjunctivitis.”
Continue reading the announcement from Nanomerics